Paris (ots/PRNewswire) – Two studies presented at World Diabetes Congress 2011 provide further evidence of the benefits to patients of early glycemic control on co-morbidities Sanofi announced today new results from sub-analyses of the First Basal INsulin Evaluation in Asia (FINE Asia) Registry study,[1] and the Cardiovascular Risk Evaluation in People with Type 2 Diabetes [...]
Tag Archive > Type 2 Diabetes
KOMBOGLYZE(TM) Receives Marketing Authorisation in the European Union for Adult Patients With Type 2 Diabetes
Paris and London, November 29 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed dose combination) that will cover the 27 Member States of the European Union. The indication for KOMBOGLYZE is as an adjunct to diet and exercise [...]
Servier Enters Into a Type 2 Diabetes partnership With Canadian Firm Prognomix Inc.
SURESNES, France and MONTRÉAL, November 8, 2011 (ots/PRNewswire) – Les Laboratoires Servier, France (Servier) and Prognomix Inc., Canada (Prognomix) announced today that they have entered into a research and development agreement aimed at identifying novel targets as part of programs meant to develop innovative type 2 diabetes and metabolic disease treatment. This collaboration will rest [...]
KOMBOGLYZE? (saxagliptin and metformin HCl Immediate-Release) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced that the Marketing Authorisation Application for KOMBOGLYZE(TM) (saxagliptin and metformin HCl immediate-release fixed dose combination) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), as an adjunct to diet and exercise, for the treatment of type 2 diabetes [...]
More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra® on top of Lantus® Than with Twice-daily Aspart Premixed Insulin
Paris (ots/PRNewswire) – – First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin Sanofi announced today data presented at the 47th Annual Meeting of the European Association for the Study of Diabetes to show that adding mealtime Apidra(R) (insulin glulisine) to [...]
Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
Paris (ots/PRNewswire) – Sanofi announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R) with the insulin delivery device SoloSTAR(R) experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed [...]
/C O R R E C T I O N — Bristol-Myers Squibb and AstraZeneca/
Paris and London (ots/PRNewswire) – In the news release, “ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe” issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read “ONGLYZA(R) [...]
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca.com) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg [...]
Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes
Paris (ots/PRNewswire) – Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from randomized clinical trials demonstrated that adding Lantus(R) (insulin glargine [rDNA] injection) to patients with type 2 diabetes, uncontrolled on oral [...]
Sanofi-aventis: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2 Diabetes
Paris (ots/PRNewswire) – Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in [...]
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
Stockholm (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride [...]
Takeda Responds to FDA Advisory Committee Recommendation
London, July 15, 2010 (ots/PRNewswire) – The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular (CV) safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda [...]
Astellas meldet Vortrag auf der Tagung der American Diabetes Association, in dem Einzelheiten zur Sicherheit und Wirksamkeit eines SGLT2-Inhibitors bei Patienten mit Typ-2-Diabetes dargelegt wurden
Tokyo, June 28, 2010 (ots/PRNewswire) – Astellas Pharma Inc. (Hauptsitz: Tokio, Präsident und CEO: Masafumi Nogimori, “Astellas”) gab bekannt, dass das Unternehmen Ergebnisse einer japanischen Phase-2-Studie zu ASP1941, einem selektiven SGLT2-Inhibitor, am 26. Juni 2010 (EST) auf den 70. Scientific Sessions der American Diabetes Association (ADA) vorgestellt hat. ASP1941 blockiert die Rückresorption von Glukose in [...]
Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to [...]
52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To Titrated Glipizide When Added To Metformin In Reducing Glycosylated Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found that the addition of ONGLYZA(TM) (saxagliptin) 5 mg to existing metformin therapy achieved [...]
